Printer Friendly

PRELIMINARY INJUNCTIONS GRANTED TO PRESERVE STATUS QUO PENDING ARBITRATION OF PATENT LICENSE DISPUTE BETWEEN DISEASE DETECTION INTERNATIONAL AND EDITEK INC.

 IRVINE, Calif., Feb. 23 /PRNewswire/ -- Disease Detection International Inc. (NASDAQ: DDII) announced that a Superior Court in California today granted preliminary injunctions requested by each of DDII and Editek Inc. in civil proceedings to determine the validity and effect of a 1985 license agreement.
 The Superior Court granted a preliminary injunction in favor of DDII restraining Editek from marketing, producing, licensing or contracting with others under Editek patents covered by the 1985 license for fields of use exclusively reserved to DDII by the license. As an exception, the preliminary injunction permits Editek to continue current research, development, testing and other activities under certain specified prior agreements until a decision is rendered.
 Under the 1985 license, rights to Editek patents and patent applications were licensed to DDII on worldwide, royalty-free exclusive basis for use in the fields of infectious disease detection in humans and veterinary diagnostics, as well as diagnosis of human pregnancy and ovulation. Editek claims it terminated the license in 1988, and DDII contends Editek did not have valid cause to terminate. The court ordered this dispute to be resolved by arbitration, as required by the license, and granted preliminary injunctions to preserve the status quo pending final resolution.
 On Jan. 4, 1993, DDII granted International Murex Technologies Corp. ("Murex") and its affiliates a non-exclusive sublicense under Editek patents rights only as to DDII's fields of use, and excluding any products which would be covered by the claims of DDII's own patent. The court granted a preliminary injunction in favor of Editek providing that the right of Murex to exercise, use or enjoy any Editek intellectual property rights under its sublicense from DDII shall not become effective pending a resolution of the Editek/DDII license dispute. DDII has been advised the Murex does not believe that Murex or its affiliates is currently engaged in the manufacture, use or sale of products which would be covered by valid patent claims of Editek.
 Each of Editek and DDII posted a $500,000 bond with the court to secure damages, if any, resulting from the issuance of its preliminary injunction.
 As previously reported, based upon opinions of DDII's counsel, DDII believes it has meritorious defenses to Editek's claim that the 1985 license was terminated.
 DDII has manufactured and sold diagnostic tests since 1988 covered by DDII's own patented technology, and has not sought to market devices developed by Editek. To date, Editek has not sought to prevent DDII from manufacturing and selling DDII's patented diagnostic tests for its own account or through previously announced agreements with licensees and distributors.
 If DDII's position as to the 1985 license is sustained, DDII may be entitled to exploit patent rights of Editek in DDII's fields of use for infectious diseases and human pregnancy and ovulation. DDII has not yet attempted to commercialize rights under Editek patents, other than the limited sublicense granted to Murex. In the opinion of DDII and its patent counsel, all patents relating to immunoassay diagnostic devices known to have been issued to Editek to date are included within the patent rights and technology covered by the 1985 license. Editek has been quoted as claiming that its U.S. patent number 5,141,875 (entitled Rotary Fluid Manipulator), issued on Aug. 25, 1992, and stemming from a U.S. patent application filed Jan. 8, 1982, is part of a portfolio of patents and patent applications, that "is extremely comprehensive, extremely valuable, and collectively provides broad offensive and defensive postures for EDI." DDII is unable to predict what value, if any, such rights would represent to DDII if its position in the pending civil proceedings is sustained.
 -0- 2/23/93
 /CONTACT: H. Thad Morris, president and CEO of Disease Detection International, 714-457-1787/
 (DDII)


CO: Disease Detection International Inc.; Editek Inc.;
 International Murex Technologies Corp. ST: California IN: MTC SU:


JB-JL -- LA011 -- 9244 02/23/93 08:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 23, 1993
Words:646
Previous Article:INTERNATIONAL TECHNOLOGY CORP. SELECTED FOR BROOKHAVEN NATIONAL LABORATORY CONTRACT
Next Article:SCOTTS ANNOUNCES SHARE REPURCHASE
Topics:


Related Articles
EDITEK SUES DISEASE DETECTION INTERNATIONAL RELATIVE TO A LICENSE AGREEMENT TERMINATED NEARLY FIVE YEARS AGO
DISEASE DETECTION INTERNATIONAL SEEKS INJUNCTION AGAINST EDITEK
EDITEK WINS PRELIMINARY INJUNCTION ROUND IN COURT
EDITEK ANNOUNCES ADVERSE RULING IN DISEASE DETECTION ARBITRATION
DISEASE DETECTION INTERNATIONAL, INC., WINS ARBITRATION BATTLE WITH EDITEK, INC. OVER VALUABLE PATENT RIGHTS
EDITEK, INC. WINS PATENT INTERFERENCE LITIGATION AGAINST MUREX CORPORATION
ALAMAR ANNOUNCES DIFCO AGREEMENT
TARGET THERAPEUTICS ANNOUNCES STATUS OF PATENT LITIGATION:
TARGET THERAPEUTICS PROVIDES UPDATE ON PATENT LITIGATION

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters